Supplementary Figure 1. BP cells behave like classic BRAFV600E melanomas after BRAF inhibition. Supplementary Figure 2. Subcutaneously implanted BP cells develop into tumors. Supplementary Figure 3. BRAF inhibition is associated with an increase in density of tumor-infiltrating T cells. Supplementary Figure 4. Kinetics of functional CD8 T cell markers. Supplementary Figure 5. BRAF inhibition is associated with an increase in overall PD-L1 and PD-L2 expression in the tumor. Supplementary Figure 6. Cell type specific changes in PD-L1 expression after BRAF inhibitors. Supplementary Figure 7. PD-1 or PD-L1 blockade synergy with BRAF inhibitors is associated with increased density of tumor-infiltrating T cells.